Literature DB >> 11677219

Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease.

S J van Deventer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11677219     DOI： 10.1053/gast.2001.29035

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  22 in total

Review 1.  Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection.

Authors:  Richard Long; Michael Gardam
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

2.  Regression of inflammatory myofibroblastic tumor of the gastrointestinal tract under infliximab treatment.

Authors:  Georgios Germanidis; Ioannis Xanthakis; Ioannis Tsitouridis; Thomas Zaramboukas; Dimitrios Kiskinis; Christos Konstantaras; Spiros Miliaras; Theodoros Sirakos; Emmanouil Pagkalos
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 3.  Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications.

Authors:  J Mudter; M F Neurath
Journal:  Gut       Date:  2006-09-06       Impact factor: 23.059

Review 4.  Intestinal macrophages: differentiation and involvement in intestinal immunopathologies.

Authors:  Benjamin Weber; Leslie Saurer; Christoph Mueller
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

5.  Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease.

Authors:  Dario Sorrentino; Claudio Avellini; Carlo Alberto Beltrami; Enrico Pasqual; Ester Zearo
Journal:  Int J Colorectal Dis       Date:  2005-06-11       Impact factor: 2.571

Review 6.  Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors:  J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

7.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Authors:  A Di Sabatino; R Ciccocioppo; B Cinque; D Millimaggi; R Morera; L Ricevuti; M G Cifone; G R Corazza
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

8.  Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.

Authors:  T Cantaert; L De Rycke; C P Mavragani; C A Wijbrandts; T B Niewold; T Niers; B Vandooren; E M Veys; D Richel; P P Tak; M K Crow; D Baeten
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

Review 9.  Maintenance of remission in Crohn's disease: current and emerging therapeutic options.

Authors:  Matthew J Brookes; Jonathon R B Green
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 10.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.